Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: A novel mechanistic hypothesis

CNS Drugs

Volumn 27, Issue 4, 2013, Pages 249-257

  Scigliano, Giulio ^a   Ronchetti, Gabriele ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADRENALIN; ALPHA 2A ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BENSERAZIDE; CARBIDOPA; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUCAGON; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ILOPERIDONE; INSULIN; LEPTIN; LEVODOPA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; MUSCARINIC RECEPTOR; NORADRENALIN; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

ABDOMINAL FAT; ADIPOSE TISSUE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY WEIGHT; CARDIOVASCULAR RISK; DIABETES MELLITUS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GLUCAGON RELEASE; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPATHETIC TONE; TORSADE DES POINTES;

ANIMALS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DOPAMINE; HUMANS; METABOLIC DISEASES; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84878218610     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0054-1     Document Type: Review

References (97)

1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
2. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am Heart J. 2005;149(1):33-45.
3. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45(1-2):21-8.
4. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
5. Kasanin J. The blood sugar curve in mental disease: II. The schizophrenia (dementia praecox) group. Arch Neurol Psychiatry. 1926;16(4):414-9.
6. Sengupta S, Parrilla-Escobar MA, Klink R, et al. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res. 2008;102(1-3):329-36.
7. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res. 2010;121(1-3):199-202.
8. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160(2):284-9.
9. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26(1):137-41.
10. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl. 2004;47:S76-9.
11. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114-26.
12. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74(4):761-811.
13. Zahn TP, Pickar D. Autonomic activity in relation to symptom ratings and reaction time in unmedicated patients with schizophrenia. Schizophr Res. 2005;79(2-3):257-70.
14. Kemali D, Maj M, Ariano MG, et al. 24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients. Neuropsychobiology. 1985;14(3):109-14.
15. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl. 2004;47:S72-5.
16. Watts DT. The effect of nicotine and smoking on the secretion of epinephrine. Ann NY Acad Sci. 1960;90:74-80.
17. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet. 1992;339:1128-30.
18. Muscat JE, Harris RE, Haley NJ, et al. Cigarette smoking and plasma cholesterol. Am Heart J. 1991;121(1 Pt 1):141-7.
19. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2007;298(22):2654-64.
20. Chiolero A, Faeh D, Paccaud F, et al. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87(4):801-9.
21. Cullen MW, Ebbert JO, Vierkant RA, et al. No interaction of body mass index and smoking on diabetes mellitus risk in elderly women. Prev Med. 2009;48(1):74-8.
22. Filozof C, Fernández Pinilla MC, Fernández-Cruz A. Smoking cessation and weight gain. Obes Rev. 2004;5(2):95-103.
23. Iino K, Iwase M, Tsutsu N, et al. Smoking cessation and glycaemic control in type 2 diabetic patients. Diabetes Obes Metab. 2004;6(3):181-6.
24. Ahren B. Autonomic regulation of islet hormone secretion: Implications for health and disease. Diabetologia. 2000;43(4):393-410.
25. Jamerson KA, Julius S, Gudbrandsson D, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21(5):618-23.
26. Arner P. Human fat cell lipolysis: Biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab. 2005;19:471-82.
27. Kahn SE, Hull RL, Utzschneider KM. Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-6.
28. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36(3):232-40.
29. O'Meara NM, Devery RA, Owens D, et al. Alterations in cellular cholesterol metabolism following administration of 6-hydroxydopamine to rabbits. Br J Pharmacol. 1992;105(2):495-9.
30. Rosmond R, Dallman MF, Björntop P. Stress related cortisol secretion in men: Relationship with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab. 1998;83(6):1853-9.
31. Amerena J, Julius S. The role of the autonomic nervous system in hypertension. Hypertens Res. 1995;18(2):99-110.
32. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study. Clin Pract Epidemol Ment Health. 2006;27(2):14.
33. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-33.
34. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.
35. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007 Nov;91(6):1063-77, viii.
36. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(Suppl. 1):1-93.
37. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: Implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32(2):289-97.
38. Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, et al. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95(1):118-25.
39. Albaugh VL, Singareddy R, Mauger D, et al. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6(8):e22662.
40. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: A prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab. 2003;88(12):5875-80.
41. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111(9):716-23.
42. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
43. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol. 2006;164(7):672-81.
44. Citrome L. Risk-benefit analysis of available treatments for schizophrenia. Psychiatric Times. 2007;1:27-30.
45. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127(3):210-51.
46. Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry. 2011;72(9):1270-6.
47. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733-59.
48. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment: Pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169-79.
49. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among medicaid patients with bipolar disorder: A nested case-control study. Pharmacotherapy. 2007;27(1):27-35.
50. Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: The CATIE-AD study. Am J Psychiatry. 2009;166(5):583-90.
51. Newcomer JW. Metabolic syndrome and mental illness. Am J Managed Care. 2007;13(11):S170-7.
52. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62:231-8.
53. Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and antipsychotics: New findings from animal model and pharmacogenomic studies. Schizophr Res Treat. 2011;2011:459284.
54. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-26.
55. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20(5):368-78.
56. Huang XF, Han M, Huang X, et al. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res. 2006;171:355-62.
57. Baptista T, Parada M, Hernandez L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats: Are D2 dopamine receptors involved? Pharmacol Biochem Behav. 1987;27(3):399-405.
58. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
59. Silvestre JS, Prous J. Research on adverse drug events: I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289-304.
60. Fabris SE, Thorburn A, Litchfield A, et al. Effect of parasympathetic denervation of liver and pancreas on glucose kinetics in man. Metabolism. 1996;45(8):987-91.
61. Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008;100(1-3):70-85.
62. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs. 2011;25(12):1035-59.
63. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain: Mechanisms and genetics. J Psychopharmacol. 2006;20(4 Suppl.):15-8.
64. van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010;121(1-3):193-8.
65. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010;20(6):359-66.
66. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: From structure to function. Physiol Rev. 1998;78(1):189-225.
67. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277(5692):93-6.
68. Murphy MB. Dopamine: A role in the pathogenesis and treatment of hypertension. J Hum Hypertens. 2000;14(Suppl. 1):S47-50.
69. Mannelli M, Delitala G, De Feo ML, et al. Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J Clin Endocrinol Metab. 1984;59(1):74-8.
70. Mannelli M, Ianni L, Lazzeri C, et al. In vivo evidence that endogenous dopamine modulates sympathetic activity in man. Hypertension. 1999;34(3):398-402.
71. 2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006;291:E1038-43.
72. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8(10):1683-707.
73. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2):123-34.
74. Brogden RN, Carmine AA, Heel RC, et al. Domperidone: A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24(5):360-400.
75. Mannelli M, Pupilli C, Fabbri G, et al. Endogenous dopamine (DA) and DA2 receptors: A mechanism limiting excessive sympathetic-adrenal discharge in humans. J Clin Endocrinol Metab. 1988;66(3):626-31.
76. Luchsinger A, Grilli M, Velasco M. Metoclopramide and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients. Am J Ther. 1998;5(2):81-8.
77. See RE, Fido AA, Maurice M, et al. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry. 1999;45(12):1653-6.
78. Zander KJ, Fischer B, Zimmer R, et al. Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology (Berl). 1981;73(1):43-7.
79. Savoy YE, Ashton MA, Miller MW, et al. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation. Schizophr Bull. 2010;36(2):410-8.
80. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45-53.
81. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-96.
82. Montiel C, Artalejo AR, Bermejo PM, et al. A dopaminergic receptor in adrenal medulla as a possible site of action for the droperidol-evoked hypertensive response. Anesthesiology. 1986;65(5):474-9.
83. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-71.
84. Roussak JB, Carey P, Harry H. Cardiac arrest after treatment with intravenous domperidone. BMJ (Clin Res Ed). 1984;289(6458):1579.
85. Abildskov JA, Lux RL. Mechanisms in adrenergic dependent onset of torsades de pointes. Pacing Clin Electrophysiol. 1997;20(1 Pt 1):88-94.
86. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: Identification and management. CNS Drugs. 2011;25(8):659-71.
87. Julius S. Abnormalities of autonomic nervous control in human hypertension. Cardiovasc Drugs Ther. 1994;8(Suppl. 1):11-20.
88. Goldstein DS, Holmes CS, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology. 2002;58(8):1247-55.
89. Scigliano G, Musicco M, Soliveri P, et al. Reduced risk factors for vascular disorders in Parkinson's disease patients: A case-control study. Stroke. 2006;37(5):1184-8.
90. Scigliano G, Ronchetti G, Girotti F, et al. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord. 2009;15(2):138-43.
91. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
92. Ebert B, Wafford KA, Whiting PJ, et al. Molecular pharmacology of gamma-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta, and gamma receptor subunit combinations. Mol Pharmacol. 1994;46(5):957-63.
93. Jaskiw GE, Popli AP. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: Therapeutic and heuristic implications. Psychopharmacology (Berl). 2004;171(4):365-74.
94. Whitsett TL, Halushka PV, Goldberg LI. Attenuation of postganglionic sympathetic nerve activity by L-dopa. Circ Res. 1970;27(4):561-70.
95. Rajfer SI, Anton AH, Rossen JD, et al. Beneficial hemodynamic effects of oral levodopa in heart failure: Relation to the generation of dopamine. N Engl J Med. 1984;310(21):1357-62.
96. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976;1(7954):292-6.
97. Parkkinen L, O'Sullivan SS, Kuoppamäki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology. 2011;77(15):1420-6.